

(19)



(11)

**EP 2 678 327 B8**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:

**C07D 333/22** <sup>(2006.01)</sup>      **C07D 409/04** <sup>(2006.01)</sup>  
**A61K 31/381** <sup>(2006.01)</sup>      **A61P 25/28** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**28.09.2016 Bulletin 2016/39**

(86) International application number:

**PCT/IB2012/050806**

(45) Date of publication and mention of the grant of the patent:

**17.08.2016 Bulletin 2016/33**

(87) International publication number:

**WO 2012/114285 (30.08.2012 Gazette 2012/35)**

(21) Application number: **12709965.3**

(22) Date of filing: **22.02.2012**

**(54) HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS**

HETEROARYLDERIVATE ALS ALPHA7-NACHR-MODULATOREN

DÉRIVÉS HÉTÉROARYLE À TITRE DE MODULATEURS DES NACHR ALPHA 7

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

- **HAJARE, Anil, Kashiram**  
Pune 411 042 (IN)
- **TILEKAR, Ajay, Ramchandra**  
Pune 411 042 (IN)
- **PALLE, Venkata, P.**  
Pune 411 042 (IN)
- **KAMBOJ, Rajender, Kumar**  
Pune 411 042 (IN)

(30) Priority: **23.02.2011 IN KO02422011**  
**09.09.2011 IN KO11842011**

(43) Date of publication of application:

**01.01.2014 Bulletin 2014/01**

(74) Representative: **Watson, Robert James et al**

**Mewburn Ellis LLP**  
**City Tower**  
**40 Basinghall Street**  
**London EC2V 5DE (GB)**

(73) Proprietor: **Lupin Limited**

**Mumbai 400055 (IN)**

(56) References cited:

**WO-A1-2008/002974**

(72) Inventors:

- **SINHA, Neelima**  
Pune 411 042 (IN)
- **JANA, Gourhari**  
Pune 411 042 (IN)
- **SACHCHIDANAND, Sachchidanand**  
Pune 411 042 (IN)
- **KURHADE, Sanjay, Pralhad**  
Pune 411 042 (IN)
- **KARCHE, Navnath, Papat**  
Pune 411 042 (IN)

- **TATSUMI ET AL.:**  
**"(+)-3-[2-(benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the alpha-7 nicotinic acetylcholine receptor",**  
**BIOORG. MED. CHEM. LETT., vol. 14, no. 14, 1**  
**January 2004 (2004-01-01), pages 3781-3784,**  
**XP002327499, ISSN: 0960-894X, DOI:**  
**10.1016/J.BMCL.2004.04.091**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 678 327 B8**

- **TATSUMI ET AL.:**  
"(R)-3'-(3-Methylbenzo(b)thiophen-5-yl)-  
spiro(1-azabicyclo(2,2,2)octane-3,5'-  
oxazolidin)-2'-one, a Novel and Potent  $\alpha_7$   
Nicotinic Acetylcholine Receptor Partial Agonist  
Displays Cognitive Enhancing Properties", J.  
MED. CHEM., vol. 49, no. 14, 1 January 2006  
(2006-01-01), pages 4374-4383, XP002538696,  
ISSN: 0022-2623, DOI: 10.1021/JM060249C  
[retrieved on 2006-06-16]

Remarks:

The file contains technical information submitted after  
the application was filed and not included in this  
specification